Amedica Corporation (AMDA) Shares are Up 57.81%

Amedica Corporation (AMDA) : Traders are bullish on Amedica Corporation (AMDA) as it has outperformed the S&P 500 by a wide margin of 21.21% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 58.86%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 57.81% in the last 1 week, and is up 20.96% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

For this week, the average consensus of the company shares are rated as a Strong Buy. The stock has recorded a twenty day Moving Average of 23.6% and the fifty day Moving Average is 5.76%. Amedica Corporation has dropped 25.19% during the last three month period . Year-to-Date the stock performance stands at -43.42%.

Amedica Corporation (AMDA) : The highest short term price target forecast on Amedica Corporation (AMDA) is $3 and the lowest target price is $2. A total of 2 equity analysts are currently covering the company. The average price of all the analysts is $2.25 with a standard deviation of $0.35.


Amedica Corporation (NASDAQ:AMDA): The stock was completely flat for the day, closing at $1.01 on Friday. The flat closing masks the intraday volatility in the stock. After opening at $1.00, the stock touched an intraday high of $1.05 and a low of $0.92. Neither the bulls nor the bears asserted their supremacy at close, due to which the stock closed completely flat. The stock previously closed at $1.01. The total trading volume on Friday was 4,341,046.

Amedica Corporation is a commercial biomaterial company. The Company is a vertically integrated silicon nitride orthopedic medical device manufacturer focused on using its silicon nitride technology platform to develop, manufacture and sell a range of medical devices. The Company markets spinal fusion products and are developing products for use in total hip and knee joint replacements. The Company markets its Valeo family of silicon nitride interbody spinal fusion devices in the United States and Europe for use in the cervical and thoracolumbar areas of the spine. The Companys Valeo interbody spinal fusion devices include Anterior Lumbar, Posterior Lumbar, Oblique Lumbar, Transforaminal Lumbar, Cervical and Corpectomy. In addition to its silicon nitride-based spinal fusion products, the Company markets a line of non-silicon nitride spinal fusion products, which allows it to provide surgeons and hospitals with a range of products.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.